ESSA Pharma Valuation
| EPIX Stock | USD 1.60 0.02 1.23% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. ESSA Pharma shows a prevailing Real Value of $1.55 per share. The current price of the firm is $1.6. Our model computes the value of ESSA Pharma from evaluating the firm fundamentals such as Current Valuation of (49.12 M), shares owned by insiders of 6.01 %, and Return On Asset of -0.17 as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that ESSA Pharma's price fluctuation is risky at this time. Calculation of the real value of ESSA Pharma is based on 3 months time horizon. Increasing ESSA Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ESSA Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ESSA Stock. However, ESSA Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.6 | Real 1.55 | Hype 1.6 | Naive 1.56 |
The intrinsic value of ESSA Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ESSA Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ESSA Pharma helps investors to forecast how ESSA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ESSA Pharma more accurately as focusing exclusively on ESSA Pharma's fundamentals will not take into account other important factors: ESSA Pharma Total Value Analysis
ESSA Pharma is currently forecasted to have valuation of (49.12 M) with market capitalization of 71.02 M, debt of 329.26 K, and cash on hands of 174.6 M. The negative valuation of ESSA Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the ESSA Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(49.12 M) | 71.02 M | 329.26 K | 174.6 M |
ESSA Pharma Asset Utilization
One of the ways to look at asset utilization of ESSA is to check how much profit was generated for every dollar of assets it reports. ESSA Pharma shows a negative utilization of assets of -0.17 percent, losing $0.001709 for each dollar of assets held by the firm. Ineffective asset utilization denotes the company is being less competent with each dollar of assets it shows. Put another way, asset utilization of ESSA Pharma shows how unsuccessful it operates for each dollar spent on its assets.ESSA Pharma Ownership Allocation
ESSA Pharma holds a total of 44.39 Million outstanding shares. The majority of ESSA Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in ESSA Pharma to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ESSA Pharma. Please pay attention to any change in the institutional holdings of ESSA Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.ESSA Pharma Profitability Analysis
Net Loss for the year was (28.54 M) with profit before overhead, payroll, taxes, and interest of 0.About ESSA Pharma Valuation
Our relative valuation model uses a comparative analysis of ESSA Pharma. We calculate exposure to ESSA Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ESSA Pharma's related companies.ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States.
ESSA Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 44.3 M |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.